RxDoctor Payments Data

German Larrain, MD

Interventional Cardiology · Wausau, WINPI 1508845090

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Abbott at 24.1% of the total. 2025 is the largest year on record at $8,767, 2.1 times the $4,191 reported in 2019.

$38,154in general payments, 2019–2025

Across 299 payments — averaging $127.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Boston Scientific$5K
  • Edwards Lifesciences$5K
  • Penumbra, Inc.$5K
  • Medtronic$5K
  • Heartflow, Inc.$3K
  • plus $7K from 22 others
$781,354in research payments, 2019–2025

Across 196 payments — averaging $3986.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Diagnostics Operations, Inc.$159K
  • Abbott$141K
  • Amgen$138K
  • Medtronic$109K
  • AstraZeneca$92K
  • CSL Behring$61K
  • plus $81K from 4 others

What the payments were for

  • Consulting fees$2,7027%
  • Travel & lodging$16,43243%
  • Food & beverage$18,86949%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,154 in reported general payments places this provider in the 85th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$243,484
Medicare patients
1,532
Services billed
3,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban612$671,816
EntrestoSacubitril/Valsartan201$249,355
VyndamaxTafamidis11$248,210
XareltoRivaroxaban157$175,379
JardianceEmpagliflozin169$173,259
Repatha SureclickEvolocumab152$134,022
MultaqDronedarone Hcl54$83,654
Praluent PenAlirocumab30$35,886
OzempicSemaglutide16$23,873
FarxigaDapagliflozin Propanediol14$17,618
CorlanorIvabradine Hcl14$12,206
Metoprolol Succinate832$11,142
Atorvastatin Calcium937$8,437
Ezetimibe362$7,158
Bumetanide229$6,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$291$920,027623 claims
NovartisEntresto$322$249,355201 claims
Johnson & JohnsonXarelto$77$175,379157 claims
Novo NordiskOzempic$210$23,87316 claims
AstraZenecaFarxiga$443$17,61814 claims
AmgenCorlanor$262$12,20614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →